Antibodies News and Research

RSS

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

A blood test for Alzheimer's on the horizon

Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer's disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.

11 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Tissue-cultured smallpox vaccine shows promise

Administration of a tissue-cultured smallpox vaccine showed signs of an effective vaccine response with no serious adverse events, according to a study in the March 11 issue of JAMA, the Journal of the American Medical Association.

11 Mar 2009

Number of cardiovascular risk factors could determine safety of IVIg treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009

Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

5 Mar 2009

Antibody key to treating variant CJD

Scientists at the University of Liverpool have determined the atomic structure of the 'binding' between a brain protein and an antibody that could be key to treating patients with diseases such as variant CJD.

4 Mar 2009

Axela introduces dotLab Amine Reactive Sensor

Axela Inc has introduced the dotLab Amine Reactive Sensor for stable covalent coupling of affinity reagents such as antibodies for use with the Axela dotLab System.

4 Mar 2009

Better understanding of immune system activation

Linda Andersson at Malmo University in Sweden has studied the ability of dendritic cells to sample the surrounding environment. To understand how different materials are taken up and what happens within the cells can for example facilitate the development of new vaccines.

3 Mar 2009

Instant immunity through chemically programmable vaccination and covalent self-assembly

The experiments, thus far performed only in mice, appear to overcome a major drawback of vaccinations - the lag time of days, or even weeks, that it normally takes for immunity to build against a pathogen.

2 Mar 2009

Epstein-Barr virus may be associated with progression of multiple sclerosis

Epstein-Barr virus (EBV), the pathogen that causes mononucleosis, appears to play a role in the neurodegeneration that occurs in persons with multiple sclerosis, researchers at the University at Buffalo and the University of Trieste, Italy, have shown.

2 Mar 2009

The obesity paradox

It's called the obesity paradox. Although obese people are more apt to suffer from inflammatory diseases, such as diabetes, heart disease, and stroke, they are also more likely to survive a major attack caused by one of those conditions.

26 Feb 2009

Antibody recognition of a highly conserved epitope across influenza viruses

The discovery of the molecule, an antibody known as CR6261, is good news for researchers who hope to design a flu vaccine that would give humans lifelong protection against a majority of influenza viruses.

26 Feb 2009

Novel approach to gene hunting uncovers possible new targets for Crohn's disease drugs

Discovering the different genes that contribute to a complex disease is like searching in the proverbial haystack for an unknown number of needles--some much smaller than others, often blending into the background, and many of them widely separated from each other.

26 Feb 2009

Research points to new antiviral drugs and universal influenza vaccines

WHAT: Researchers at The Scripps Research Institute in La Jolla, California, supported in part by the National Institutes of Health, have identified a common Achilles' heel in a wide range of seasonal and pandemic influenza A viruses.

26 Feb 2009

Immune system found to be more versatile than previously thought

By studying how mice fight off infection by intestinal worms - a condition that affects more than 1 billion people worldwide - scientists have discovered that the immune system is more versatile than has long been thought.

26 Feb 2009

Xencor and CSL Limited establish antibody optimization collaboration

Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

23 Feb 2009